SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending due to a significant after-hours drop following the announcement of a $1 billion convertible note offering, despite recent strong earnings. The community is debating whether this offering signals growth financing or potential dilution, with some viewing it as a buying opportunity while others express concern about the short-term impact. Discussion also involves the company's AI data center plans and potential ERCOT approval.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with the community debating whether the stock will surge or experience a post-earnings pullback. Bullish sentiment is fueled by potential S&P 500 inclusion, possible rate cuts, and the potential addition of crypto trading to the platform. Discussions also highlight SoFi's transition into a comprehensive financial services provider and positive technical indicators.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

DGXX is trending as investors focus on the company's potential in AI and data centers, with community members pointing to its advantageous position in the sector, zero debt, and increasing volume. Conversations revolve around potential tenant news and the possibility of a significant run, fueled by growing interest from institutional investors. Some traders note its potential for significant growth given recent partnerships and expansion plans.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is trending amid discussions surrounding its pending acquisition by CoreWeave (CRWV), with a shareholder vote approaching. Community talking points include whether the all-stock deal undervalues CORZ, especially given its infrastructure and potential in the AI data center space, and what the potential implications of a 'yes' or 'no' vote will be for both companies.

ETHZilla Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZ is trending due to discussions around a recent reverse stock split and its potential impact on the company's valuation. The community is actively debating the implications of the split, a stock buyback program, and the company's Ethereum holdings. Some traders are pointing to potential upside due to the buyback, while others express concern about dilution and management strategy.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond ($BBBY) is trending as traders discuss its recent earnings report, which showed improvements in key metrics despite a revenue miss, and a lack of forward guidance from management. Community members are also speculating on the company's future direction, potential for meme stock resurgence, and the impact of its blockchain initiatives through Tzero.  The stock is further fueled by the speculative chatter surrounding warrant distribution and any potential impact.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following news of its entrance into the AI accelerator chip market, directly challenging Nvidia and AMD; this includes a partnership with Saudi Arabia. Community members are actively debating whether Qualcomm can truly compete in the AI hardware space, while some highlight its attractive valuation compared to competitors.  Discussions also involve potential collaborations and impacts on related stocks.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the following segments: Advanced Technology Solutions (ATS), and Connectivity and Cloud Solutions (CCS). The Advanced Technology Solutions (ATS) segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The Connectivity and Cloud Solutions (CCS) segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is trending due to strong Q3 earnings and raised guidance, particularly for FY26, with the community highlighting a "monster" beat. Investors are optimistic about the company's prospects in the data center and AI infrastructure space, with some drawing comparisons to $NVDA's early growth. Community members also noted increased risks and uncertainties related to US trade policy.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending due to a paused clinical trial following a patient experiencing liver enzyme elevations, sparking community debate about the severity and potential buying opportunities. Despite analyst price target reductions, many view the drop as an overreaction, citing the company's strong financial position and potential for risk mitigation. Community members are weighing the news against analyst buy ratings and the long-term potential of gene editing.

SPDR Series Trust - SPDR Biotech ETF

SPDR S&P Biotech ETF

XBI is trending as Novartis' acquisition of Avidity Biosciences has sparked optimism in the biotech sector, with the community actively discussing potential M&A targets and a possible sector-wide repricing. Chatter suggests institutional money is flowing back into biotech after a long period of undervaluation. Some are pointing to SELLAS Life Sciences, suggesting that recent moves are positioning it for a buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company announced the exercise of existing warrants held by an institutional investor.</li><li>The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.&nbsp;</li><li>The transaction is expected to close on or about October 28, the company said.&nbsp; &nbsp;</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 6% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.The warrants were previously issued in March and August 2024, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Group-Announces-Exercise-of-Existing-Warrants-Held-by-a-Current-Institutional-Investor-for-31-Million-in-Gross-Proceeds/default.aspx">said</a>. The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.The new warrants will be exercisable immediately and will expire five years from the date of issuance, the company said.The closing of the translation is expected to occur on or about October 28, it added.Sellas is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics. Its lead product candidate, called GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in an array of tumor types.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/SLS"> SLS stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user recommended holding the stock, opining that it will now go higher.<stembedurl>https://stocktwits.com/Kevoo/message/633843705</stembedurl>Another dismissed concerns of dilution, terming the warrant exercise a “not that big deal.”<stembedurl>https://stocktwits.com/Risulom/message/633841655</stembedurl> In September, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-in-spotlight-after-institutional-investor-exercises-existing-warrants/chwNYhvRdvv">announced</a> that an institutional investor had exercised the warrants it held to purchase up to 19.69 million shares of the company’s common stock for gross cash proceeds of approximately $23.6 million. The warrants were previously issued in January 2025, the company then said.SLS stock is up by 80% this year and by about 54% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dyne-therapeutics-stock-soars-after-rival-avidity-biosciences-gets-acquired-by-novartis/cLG0X2XR3u7">Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Why Is SELLAS Life Sciences Stock Falling Today?

Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 5% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.

Why Is SELLAS Life Sciences (SLS) Stock Falling Today?

Equity

Shares of Sellas Life Sciences rose over 7% in premarket trading on Thursday as investors turned optimistic ahead of the company’s Saturday presentation on new preclinical data for its experimental cancer drug SLS009 at the European Society for Medical Oncology Congress 2025 in Berlin.Promising Data In Rare Leukemia&nbsp;Sellas said its selective CDK9 inhibitor, SLS009, showed significant activity in treating T-cell prolymphocytic leukemia (T-PLL), both as a standalone therapy and in combination with venetoclax.&nbsp;In a patient-derived xenograft model of relapsed or refractory T-PLL, SLS009 monotherapy extended survival to 7.4 weeks, while the combination reached 7.9 weeks, compared with 4.4 weeks for venetoclax alone, marking a statistically significant improvement. The company said both regimens also reduced circulating T-PLL cells more effectively and were well tolerated.&nbsp;Faster Clinical TranslationDragan Cicic, Chief Development Officer at Sellas, said the findings provide “important preclinical evidence” that CDK9 inhibition may play a key role in addressing this aggressive and difficult-to-treat leukemia.Francisco Vega of the University of Texas MD Anderson Cancer Center, the study’s lead author, said the new T-PLL xenograft model “closely mirrors” the behavior and progression of the disease in humans. It allows for faster translation of promising preclinical data into the clinic.Pipeline Expands Beyond LeukemiaSLS009 is one of Sellas’ key oncology assets, alongside its lead WT1-targeting immunotherapy, GPS, licensed from Memorial Sloan Kettering Cancer Center. The company said both candidates are designed to address cancers with poor prognostic factors and limited treatment options.Stocktwits Bulls Cheer Upcoming PresentationOn Stocktwits, retail sentiment for Sellas was ‘extremely bullish’ amid a 50% surge in 24-hour message volume.One user cheered the global attention around the stock, noting strong overnight interest and hinting at excitement ahead of the company’s planned Virtual R&amp;D Day on Oct.29.<stembedurl>https://stocktwits.com/Hannibal_Smith/message/632520690</stembedurl>Another said they hoped Sellas would release both the new data and a buyout announcement at the same event, joking that such a move could send the stock straight to 125 a share.<stembedurl>https://stocktwits.com/Mazzy85/message/632517776</stembedurl><a href="https://stocktwits.com/symbol/SLS">Sellas’ stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sellas’ stock (SLS) has more than doubled so far in 2025. | Image source: Getty Images

Sellas Life Sciences Stock Jumps Over 7% Premarket: Buzz Builds Ahead Of Weekend Cancer Drug Presentation In Berlin

The company said its cancer drug SLS009 showed strong preclinical results in T-cell prolymphocytic leukemia, improving survival and reducing tumor burden both alone and in combination with venetoclax. 

SELLAS Life Sciences Group (SLS) announced on Monday that preclinical data support its SLS009 as a monotherapy or in combination with Venetoclax for treating a rare and highly aggressive form of mature T-cell leukemia.The biopharmaceutical company said that data supporting the drug in T-cell prolymphocytic leukemia will be presented at the European Society for Medical Oncology Congress 2025, being held October 17 to October 21, in Berlin, Germany. T-PLL or T-cell prolymphocytic leukemia is a rare, aggressive type of mature T-cell leukemia that primarily affects older adults, characterized by the rapid growth of cancerous T-cells.SELLAS <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-to-Present-In-Vivo-Preclinical-Data-Demonstrating-Statistically-Significant-Survival-Benefit-of-SLS009-in-T-Cell-Prolymphocytic-Leukemia-at-the-European-Society-for-Medical-Oncology-ESMO-Congress-2025/default.aspx">said</a> that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference. The combination regimen, which prolonged overall survival to 7.9 weeks, was also well tolerated in the study, the company said.Chief Development Officer at SELLAS, Dragan Cicic, said that the results from the study are “highly encouraging” and noted that T-PLL has minimal treatment options.SLS shares traded 5% higher at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLS">SLS stock</a> remained in the ‘bullish’ territory, while message volume increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:622/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_11_30_56_AM_png_b0f4827381.webp" alt="SLS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="622" height="61"><figcaption>SLS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user wondered why the stock didn’t rally further on the news.<stembedurl>https://stocktwits.com/SunnySeed/message/632108231</stembedurl>SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.SLS stock has nearly doubled this year and is up about 60% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/whats-driving-the-rally-in-ndra-stock-today/ch6Sk9VR3kY">What’s Driving The Rally In NDRA Stock Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment

SELLAS said that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference.

Sellas Life Sciences Group, Inc. (SLS) on Thursday announced that an institutional investor has exercised the warrants it held to purchase up to 19.69 million shares of the company’s common stock for gross cash proceeds of approximately $23.6 million. The warrants were previously issued in January 2025.In consideration for the immediate exercise of the warrants in full, the investor will receive new unregistered warrants in a private placement to purchase up to 19.69 million shares of its common stock at an exercise price of $1.88. These warrants will be exercisable immediately and will expire five years and six months from the date of issuance, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Group-Announces-Exercise-of-Existing-Warrants-Held-by-a-Current-Institutional-Investor-for-23-6-Million-in-Gross-Proceeds/default.aspx">said</a>.The closing of the transaction is expected to occur on or about Sept. 12, 2025, subject to satisfaction of customary closing conditions.Sellas is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for cancer. Its lead product candidate, called GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in an array of tumor types. The company is also developing SLS009 in the treatment of Acute Myeloid Leukemia. &nbsp;On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘normal’ levels. Shares of the company were fell over 2% at the time of writing.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_33_53_PM_png_42e9b0a3c2.webp" alt="SLS's Sentiment Meter and Message Volume as of 12:34 p.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>SLS's Sentiment Meter and Message Volume as of 12:34 p.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded skeptical about the new warrants.<stembedurl>https://stocktwits.com/RandomInvestor777/message/628334051</stembedurl>Another user noted they have added to their position.<stembedurl>https://stocktwits.com/SomedayisNow/message/628326459</stembedurl>SLS stock is up 76% this year and approximately 39% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wolfpack-research-reveals-short-position-in-faraday-future/chwNmHARdvm">Wolfpack Research Reveals Short Position In EV Maker Faraday Future</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants

In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of the company's common stock.

In consideration for the immediate exercise of the warrants in full, the institutional investor will receive new, unregistered warrants in a private placement to purchase up to 19.69 million shares of the company's common stock at an exercise price of $1.88. 


SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

SELLAS Life Sciences Group (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

Galena Biopharma Upgraded to Buy: Here's What You Should Know

Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful...

SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
SLS stock results show that SELLAS Life Sciences Gr missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...

Sellas Life Sciences files to sell 13.03M shares of common stock for holders

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc